Page 19 - Greg Laub News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Following is a transcript of their remarks: Vinay Prasad, MD: I'm back with Dr. Aaron Goodman and Dr. Al-Ola Abdallah and we're talking about ASH and multiple myeloma. We have an exciting study to discuss, the FORTE study. This is a three-arm study that looks at carfilzomib-containing regimens, which, to my knowledge, is not the official standard of care in multiple myeloma in the frontline setting, although some believe it plays a role, and they ask a very provocative question about the role of transplant and maintenance. Dr. Goodman, I wonder if you might summarize the FORTE study. What is ...

Following is a transcript of their remarks: Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year's San Antonio Breast Cancer meeting. I'm Hope Rugo, professor of medicine at the University of California San Francisco's Comprehensive Cancer Center, and I'm joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco's Comprehensive Cancer Center. Thanks for joining me...

Following is a transcript of their remarks: Susan O'Brien, MD: Hi, everyone, and welcome to this roundtable where we're going to discuss CLL presentations at ASH 2020 this year. I'm Dr. Susan O'Brien from the Chao Family Comprehensive Cancer Center at the University of California in Irvine, and I'm joined by two esteemed colleagues, Dr. Jennifer Brown from Dana-Farber and Dr. Anthony Mato from Memorial Sloan Kettering. We have two presentations today on the TRANSCEND clinical trial, and that is an interesting CAR-T trial of liso-cel which targets CD19, like many of the other CAR-Ts, but is a ...

Following is a transcript of their remarks: Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year's San Antonio Breast Cancer meeting. I'm Hope Rugo, professor of medicine at the University of California San Francisco's Comprehensive Cancer Center, and I'm joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco's Comprehensive Cancer Center. Thanks for joining me...

Following is a transcript of their remarks: Vinay Prasad, MD: I'm back with Aaron Goodman and Dr. Al-Ola Abdallah and we're talking about selinexor. Aaron, selinexor, good drug or great drug? How would you characterize this drug? Aaron Goodman, MD: I would characterize it as an awful drug. Prasad: Awful drug? Prasad: And why is that, sir? Goodman: Well, $2,200 to $4,000 a month, so it's clearly not cheap, yet to date there is no data that it makes the patients live longer and the toxicity profile, I would say, is not favorable. The drug company would like to remind us that it does have a nove...